Post Content
CADTH recommends that Remsima SC be reimbursed by public drug plans as maintenance treatment for adults with moderately to severely
We recommend that Myalepta should be reimbursed by public drug plans as an adjunct to diet as a replacement therapy
CADTH recommends that public drug plans reimburse Hemgenix for the treatment of hemophilia B if certain conditions are met.
CADTH recommends that Livmarli should be reimbursed by public drug plans for the treatment of cholestatic pruritus in patients with
Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. It is estimated that 85% to 90% of
Relapsing-remitting multiple sclerosis (RRMS), the most common disease course of multiple sclerosis (MS), is a chronic immune-mediated disease with clearly
Chronic pain is pain that lasts beyond 3 months. Chronic non-cancer pain conditions include osteoarthritis, low back pain, musculoskeletal pain,
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most common toxicities secondary to T-cell engager
Registration No: 771800548 Contact Number : +91-8249516996
